Patent application number | Description | Published |
20080293934 | Method for Chiral Inversion of (S)-(+)-and (R)-(-)-10,11-Dihydro-10-Hydroxy-5H-Dibenz/B,F/Azepine-5-Carboxamide and Optically Enriched Mixtures Thereof - A method for chiral inversion of optically pure or optically enriched mixtures of (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (I) and (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide (II). | 11-27-2008 |
20090203902 | Asymmetric catalytic reduction of oxcarbazepine - A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX | 08-13-2009 |
20090221656 | Drug Combinations - A combination comprising at least two components selected from: | 09-03-2009 |
20100036127 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 02-11-2010 |
20100093817 | Compounds - This invention relates to new 6,8-difluorochroman-3-yl-1,3-dihydroimidazole-2-thiones, their preparation, and their use as a medicament. | 04-15-2010 |
20100113799 | Process for the Preparation of (R) - 5 - (2-Aminoethyl) -1- (6, 8-Difluorochroman-3-YL) -1,3-Dihydroimidazole-2-Thione - A process for making (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione and pharmaceutically acceptable salts thereof, and for making intermediates useful in the formation of said compound. | 05-06-2010 |
20100121073 | Process for the Preparation of (R)-5-(2-Aminoethyl)-1-(6,8-Difluorochroman-3-YL)-1,3-Dihydroimidazole-2-- Thione - A process for making (R)-5-(2-aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione and pharmaceutically acceptable salts thereof, and for making intermediates useful in the formation of said compound. | 05-13-2010 |
20100137390 | 1,3-Dihydroimidazole-2-Thione Derivatives as Inhibitors of Dopamine-Beta-Hydroxylase - Compounds of formula I and a method for their preparation are described, where R | 06-03-2010 |
20100217009 | Process for Preparing Chroman Derivatives - A process for preparing a compound of formula (22), comprising reducing a compound of formula (21), to produce a compound of formula (23), followed by the hydrogenolysis of the compound of formula 23 in a solvent comprising a C | 08-26-2010 |
20100298580 | Process for the Preparation of 2H-Chromene-3-Carbamate Derivatives - Compounds of formula I, V, VI and II, and processes for their preparation, | 11-25-2010 |
20110053997 | Salts and Crystal Forms - The present invention relates to novel salts of the compound (R)-5-(2-Aminoethyl)-1-(6,8-difluorochroman-3-yl)-1,3-dihydroimidazole-2-thione, polymorphs of the salts and methods of their preparation. | 03-03-2011 |
20110112301 | CRYSTAL FORMS OF 5-[3-(2,5-DICHLORO-4, 6-DIMETHYL-1-OXY-PYRIDINE-3-YL)[1,2,4] OXADIAZOL-5-YL]-3-NITROBENZENE-1,2-DIOL - This invention relates to novel polymorphs of (HO) | 05-12-2011 |
20110112303 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 05-12-2011 |
20110166360 | Catalytic Process for Asymmetric Hydrogenation - A process for preparing the S or R enantiomer of a compound of formula A, | 07-07-2011 |
20110237803 | Process - A process for preparing the S or R enantiomer of a compound of formula A, | 09-29-2011 |
20110301204 | ADMINISTRATION REGIME FOR NITROCATECHOLS - The present invention relates to novel dosage regimens for compounds of formula I: where the substituents are as defined in the specification. | 12-08-2011 |
20130041146 | Asymmetric Catalytic Reduction of Oxcarbazepine - A process for preparing (S)-(+)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide or (R)-(−)-10,11-dihydro-10-hydroxy-5H-dibenz/b,f/azepine-5-carboxamide, by reduction of oxcarbazepine in the presence of a catalyst and a hydride source is disclosed. The catalyst is prepared from a combination of [RuX | 02-14-2013 |
20140031561 | Crystalline Forms and Processes for Their Preparation - The present invention relates to crystalline Form A of 1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro-5-[2-[(phenylmethyl)amino]ethyl]-2H-imidazole-2-thione and crystalline Form B of 1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro-5-[2-[(phenylmethyl)amino]ethyl]-2H-imidazole-2-thione, processes for preparing the forms and their uses in medicine. The present invention also relates to the amorphous form of 1-[(3R)-6,8-difluoro-3,4-dihydro-2H-1-benzopyran-3-yl]-1,3-dihydro-5-[2-[(phenylmethyl)amino]ethyl]-2H-imidazole-2-thione processes for preparing it and its uses in medicine. | 01-30-2014 |
20140221668 | Process - The present invention relates to a process for preparing (R)-5-(2-(benzylamino)ethyl)-1-(6,8-difluorochroman-3-yl)-1H-imidazole-2(3H)-thione, and pharmaceutically acceptable salts thereof, especially the hydrochloride salt. The invention also relates to a process for making intermediates useful in the formation of said compound, and to the intermediates, per se. | 08-07-2014 |
20140350057 | CHEMICAL COMPOUND USEFUL AS INTERMEDIATE FOR PREPARING A CATECHOL-O-METHYLTRANSFERASE INHIBITOR - There is disclosed a methylated intermediate which may be demethylated to provide an inhibitor of catechol-O-methyltransferase useful in the treatment of Parkinson's disease. Also disclosed are methods of making and using said intermediate. | 11-27-2014 |